Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack W. Schuler purchased 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were bought at an average price of $18.98 per share, for a total transaction of $379,600.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Accelerate Diagnostics, Inc. (AXDX) traded up $1.30 during midday trading on Friday, reaching $22.45. 590,532 shares of the company’s stock were exchanged, compared to its average volume of 337,030. Accelerate Diagnostics, Inc. has a one year low of $16.75 and a one year high of $30.45.

TRADEMARK VIOLATION WARNING: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/18/jack-w-schuler-purchases-20000-shares-of-accelerate-diagnostics-inc-axdx-stock.html.

AXDX has been the topic of several research analyst reports. BidaskClub lowered shares of Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Zacks Investment Research lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Finally, ValuEngine lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Three investment analysts have rated the stock with a sell rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $33.00.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc increased its stake in Accelerate Diagnostics by 0.3% in the first quarter. Legal & General Group Plc now owns 5,123 shares of the medical research company’s stock valued at $123,000 after purchasing an additional 15 shares during the period. CLS Investments LLC acquired a new position in Accelerate Diagnostics in the second quarter valued at $137,000. Quantbot Technologies LP acquired a new position in Accelerate Diagnostics in the second quarter valued at $228,000. UBS Asset Management Americas Inc. acquired a new position in Accelerate Diagnostics in the second quarter valued at $243,000. Finally, SG Americas Securities LLC increased its stake in Accelerate Diagnostics by 87.8% in the second quarter. SG Americas Securities LLC now owns 11,054 shares of the medical research company’s stock valued at $302,000 after purchasing an additional 5,169 shares during the period. Institutional investors own 44.44% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Insider Buying and Selling by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Stock Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related stocks with our FREE daily email newsletter.